Skip to main content

Table 2 Relationship between adverse events and everolimus blood concentration

From: Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study

  Total (n = 10) Everolimus blood concentration just before discontinuation or dose reduction (ng/mL)
≤ 15.3 (n = 5) >  15.3 (n = 5)
  All grades Grade 3 or 4 All grades Grade 3 or 4 All grades Grade 3 or 4
Number of patients
 Any event 8 5 3 2 5 3
 Fatigue 1 0 0 0 1 0
 Nausea 1 0 0 0 1 0
 Vomiting 1 0 0 0 1 0
 Mucosal inflammation 5 0 2 0 3 0
 Diarrhea 1 0 0 0 1 0
 Rash 2 0 1 0 1 0
 Pneumonitis 4 2 2 1 2 1
 Increased aspartate aminotransferase 2 0 0 0 2 0
 Increased alanine transaminase 2 0 0 0 2 0
 Increased alkaline phosphatase 3 0 0 0 3 0
 Increased γ-glutamyltransferase 1 1 0 0 1 1
 Leukopenia 3 2 1 1 2 1
 Neutropenia 2 0 1 0 1 0
 Thrombocytopenia 2 0 0 0 2 0
 Anemia 2 0 0 0 2 0
 Hypoalbuminemia 1 1 0 0 1 1
 Hyperglycemia 2 1 0 0 2 1